Prevention of Pressure Ulcers in Patients at Medium to High Risk of Developing Pressure Ulcers and Using the DOMUS 4 / AUTO Motorized Air Mattress

Sponsor
Wellell France (Industry)
Overall Status
Completed
CT.gov ID
NCT05472974
Collaborator
Clin-Experts (Industry)
86
5
10.1
17.2
1.7

Study Details

Study Description

Brief Summary

The aim of the study is to determine the clinical value of using a powered alternating pressure air mattress (P-APAM) in the prevention of pressure injury (PI) in patients at medium to high risk.

This study is noncomparative, observational study.

Patients older than 18 years of age, with a medium to high risk of PI, without PI, up during the day, and lying more than 15 hours a day on a specific P-APAM were included. The study was conducted in nursing homes, and in long-stay geriatrics department.

Patients are followed up for 35 days. The use of the P-APAM is associated with the usual PI prevention measures. The primary outcome is the percentage of patients who developed between day 0 and day 35 at least one PI of at least stage 2 on the sacrum, spine, or heel. Secondary endpoints are patient assessments of comfort, caregiver satisfaction, mattress noise level, and mattress safety.

Condition or Disease Intervention/Treatment Phase
  • Device: Use of a powered alternating pressure air mattress

Study Design

Study Type:
Observational
Actual Enrollment :
86 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prevention of Pressure Ulcers in Patients at Medium to High Risk of Developing Pressure Ulcers and Using the DOMUS 4 / AUTO Motorized Air Mattress: Non-interventional Study
Actual Study Start Date :
Sep 17, 2018
Actual Primary Completion Date :
Jul 22, 2019
Actual Study Completion Date :
Jul 22, 2019

Outcome Measures

Primary Outcome Measures

  1. percentage of patients who developed at least one stage 2 pressure injury [35 days after installation on the mattress (at day 35)]

    Percentage of patients who developed at least one stage 2 PI of the sacrum, backbone, or heel (areas of support when lying down)

Secondary Outcome Measures

  1. Percentage of patients who developed a o pressure injury (any stage), other than those of the sacrum, backbone, or heel between [35 days after installation on the mattress (at day 35)]

  2. Assessment by the patient (or family or staff in the case of incapacity) of the comfort of the mattress (general comfort, stability) [35 days after installation on the mattress (at day 35)]

    On a scale from 0 (not satisfied at all) to 4 (very satisfied)

  3. Assessment by the nursing staff with the use of the mattress (implementation, cleaning maintenance turning, changing to a sitting position) [35 days after installation on the mattress (at day 35)]

    On a scale from 0 (not satisfied at all) to 4 (very satisfied)

  4. Assessment of the degree of maceration [35 days after installation on the mattress (at day 35)]

    On a scale from 1 (constantly moist) to 4 rarely moist

  5. Assessment of mattress safety [At day 35]

    by collecting any adverse event or mattress malfunction during the follow up

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Patient over 18 years old

  • Patient with a medium to high risk of developing pressure ulcers (clinical judgment and a score of [10 to 14] on the Braden scale (6 (maximum risk) to 23 (no risk))

  • Patient without pressure injury on the day of inclusion

  • Patient up during the day, lying between 3 p.m. and 8 p.m. a day on a Domus 4 / AUTO mattress

  • Patient with a weight < 200 kg

  • Patient (or a trusted third party) having been informed of the study and agreeing to participate

Exclusion Criteria:
  • Patient at end of life (estimated life expectancy less than 6 months)

  • Malnourished patient according to the french health authority (Haute Autorité de la santé) definition*

  • For adults under 70:
  • weight loss ≥ 5% in one month or ≥ 10% in six months

  • or body mass index (BMI) ≤ 18.5 (excluding constitutional thinness)

  • for adults over 70:

  • weight loss ≥ 5% in one month or ≥ 10% in six months

  • or BMI ≤ 21

  • or Mini Nutritional Assessment (MNA) ≤ 17 (/30)

  • or albuminemia < 35 g/L

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ehpad Du Parc Chateau D'Abondant Abondant France
2 Ehpad Esbv Bauge En Anjou France
3 Ehpad Residence Le Parc Fontenay-aux-Roses France
4 Ehpad Duc de Lorge Saint-Jean-d'Illac France
5 Ehpad Villa Du Tertre Saint-Parres-aux-Tertres France

Sponsors and Collaborators

  • Wellell France
  • Clin-Experts

Investigators

  • Principal Investigator: Sylvie MEAUME, Pr, Hôpital ROTSCHILD

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wellell France
ClinicalTrials.gov Identifier:
NCT05472974
Other Study ID Numbers:
  • 2018-A01274-51
First Posted:
Jul 25, 2022
Last Update Posted:
Jul 26, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Wellell France
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 26, 2022